

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10565296
	Filing Date		2007-02-15
	First Named Inventor		Britton et al.
	Art Unit		1625
	Examiner Name		T.V. Oh
	Attorney Docket Number		PR60351USw

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5686460	A	1997-11-11	Nicolai et al.	
	2	6043279	A	2000-03-28	Boehm et al.	
	3	2001021715	A	2001-09-13	Delorme et al.	
	4	3936493	A	1976-02-03	Karmas	
	5	4857516	A	1988-07-06	Terao et al.	
	6	5432175	A	1995-07-11	Piwinski et al.	
	7	6455545	A	2002-09-24	Delorme et al.	
	8	3760007	A	1973-09-18	Steinman	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10565296	
		Filing Date		2007-02-15	
		First Named Inventor		Britton et al.	
		Art Unit		1625	
		Examiner Name		T.V. Oh	
		Attorney Docket Number		PR60351USw	

9	20021156	A	2002-08-22	Boyd et al.	
---	----------	---	------------	-------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2002008865	JP		2002-01-11	Matsushita Denki Sangyo KK		<input checked="" type="checkbox"/>
	2	9415901	WO	A1	1994-07-21	Ligand Pharmaceuticals Inc.		<input type="checkbox"/>
	3	9219585	WO	A1	1992-11-12	Asahi Kasei Kogyo Kabushiki Kaisha		<input type="checkbox"/>
	4	0244141	WO	A1	2002-06-06	Schering Corp.		<input type="checkbox"/>
	5	9703046	WO	A1	1997-01-30	Schering AG		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10565296	
		Filing Date		2007-02-15	
		First Named Inventor		Britton et al.	
		Art Unit		1625	
		Examiner Name		T.V. Oh	
		Attorney Docket Number		PR60351USw	

	6	9857922	WO	A1	1998-12-23	Sumitomo Chem. Co. Ltd.	<input type="checkbox"/>
	7	03016270	WO	A1	2003-02-27	Bristol-Myers Squibb Pharma Co.	<input type="checkbox"/>
	8	06332206	JP		1994-12-02	Konica Corp.	<input checked="" type="checkbox"/>
	9	9348934	AU		1994-04-21	Loctite Corp.	<input checked="" type="checkbox"/>
	10	06051546	JP		1994-02-25	Ricoh	<input checked="" type="checkbox"/>
	11	3158852	JO		1991-07-08	Fuji Photo Film KK	<input checked="" type="checkbox"/>
	12	3015853	JO		1991-01-24	Kao Corp.	<input checked="" type="checkbox"/>
	13	2285356	JO		1990-11-22	Kao Corp.	<input checked="" type="checkbox"/>
	14	2264263	JO		1990-10-29	Rocoh KK	<input type="checkbox"/>
	15	308839	EP	A2	1981-03-29	Hoechst Aktiengesellschaft	<input type="checkbox"/>
	16	392805	EP	A2	1990-04-10	Mitsui Toastsu Chem	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10565296	
Filing Date	2007-02-15	
First Named Inventor	Britton et al.	
Art Unit	1625	
Examiner Name	T.V. Oh	
Attorney Docket Number	PR60351USw	

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	GILBERT, JACQUES ET AL.; Cytotoxicity and Antiestrogenicity of a Novel Series of Basic Diphenylethylenes; Journal of Medicinal Chemistry; 1997; 40; 1104-1111;	<input type="checkbox"/>
	2	GARG S. ET AL.; Structure-Activity Relationship of Estrogens: A Study Involving Cyclofenyl As The Model Compound; J. Steroid Biochem.; 1983; 18; 89-95;	<input type="checkbox"/>
	3	LAIOS I. ET AL.; Mechanisms Governing the Accumulation of Estrogen Receptor Alpha in MCF-7 Breast Cancer Cells Treated with Hydroxytamoxifen and Related Antiestrogens; Journal of Steroid Biochemistry & Molecular Biology; 2003; 87; 207-221;	<input type="checkbox"/>
	4	WATTS C.K.W. ET AL.; Studies on the Ligand Specificity and Potential Identity of Microsomal Antiestrogen-Binding Sites; Molecular Pharmacology; 1987; 31; 541-551;	<input type="checkbox"/>
	5	Database Search Conducted By GlaxoSmithKline, March 27, 2003;	<input type="checkbox"/>
	6	DURANI S. ET AL.; A Possible Basis for Structure-Function Relationship of Estrogens; International Journal of Quantum Chemistry; 1981; XX; 71-83;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.